AITL typically involves the expression of follicular helper T cell (TFH) markers, with positivity for two or more markers such as those encoded by BCL6, CD10, CXCL13, PD-1, or ICOS. Most patients are diagnosed at an advanced stage. This evidence concerns the gene BCL6 and angioimmunoblastic T-cell lymphoma.